Trovagene Raises $15M In PIPE

San Diego-based molecular diagnostics developer Trovagene announced this morning that it has raised $15M in a registered direct offering of its common stock. The publicly held company, which trades on the NASDAQ as TROV, said the shares were sold directly to an un-named institutional investor. The company said the new funding will go towards research and development activities and for working capital and other general corporate purposes.